Patents by Inventor Stefan Jochen KEMMLER
Stefan Jochen KEMMLER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139304Abstract: The present invention discloses a conjugate comprising an antigen (for example a saccharide antigen) covalently linked to a Pseudomonas aeruginosa PcrV carrier protein comprising an amino acid sequence which is at least 80% identical to the sequence of SEQ ID NO:1-4, wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the P. aeruginosa PcrV carrier protein. The invention also discloses Pseudomonas aeruginosa PcrV proteins that contain glycosylation site consensus sequences.Type: ApplicationFiled: August 31, 2022Publication date: May 2, 2024Inventors: Christiane Marie-Paule Simone Jeanne FERON, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Julien Laurent QUEBATTE
-
Publication number: 20240100140Abstract: The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharide comprising one or more repeat unit(s) ?4)-?-D-Glcp-(1?3)-[[?-L-Rhap-(1?2)]-[Gro-(2?P?3)]-?-D-Galp-(1?4)]-?-L-Rhap-(1?. Also provided are conjugates comprising a ?4)-?-D-Glcp-(1?3)-[[?-L-Rhap-(1?2)]-[Gro-(2?P?3)]-?-D-Galp-(1?4)]-?-L-Rhap-(1?, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.Type: ApplicationFiled: April 6, 2023Publication date: March 28, 2024Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Amirreza FARIDMOAYER, Rainer FOLLADOR, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Gerd Martin LIPOWSKY, Gerald Johann POSCH, Fabio SERVENTI
-
Patent number: 11931405Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: GrantFiled: July 28, 2022Date of Patent: March 19, 2024Assignees: GlaxoSmithKline Biologicals S.A.Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
-
Patent number: 11819544Abstract: The present invention discloses modified Staphylococcus aureus ClfA proteins that contain glycosylation site consensus sequences. The invention also discloses a conjugate comprising a modified ClfA protein and an antigen (for example a Staphylococcus aureus saccharide antigen), wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the modified ClfA protein.Type: GrantFiled: December 19, 2018Date of Patent: November 21, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Amirreza Faridmoayer, Sabina Marietta Gerber, Stefan Jochen Kemmler
-
Publication number: 20230346902Abstract: A composition comprising Shigella-Tetravalent (4-valent Shigella) bioconjugates. That encompasses the Shigella O-polysaccharide antigens of serotypes Shigella flexneri 2a, 3a, 6 and Shigella sonnei covalently linked to the protein carrier.Type: ApplicationFiled: June 17, 2021Publication date: November 2, 2023Applicant: GlaxoSmithKline Biologicals SAInventors: Martin Edward BRAUN, Rainer FOLLADOR, Stefan Jochen KEMMLER
-
Publication number: 20230293657Abstract: The present invention relates to the field of immunogenic compositions and vaccines, their manufacture, host cells which can be used in their manufacture and the use of such immunogenic compositions and vaccines in medicine. More particularly, it relates to Klebsiella pneumoniae O-antigens, conjugates comprising a K. pneumoniae O-antigen, host cells suitable for their production and immunogenic compositions or vaccines containing at least one Klebsiella pneumoniae O-antigen.Type: ApplicationFiled: June 17, 2021Publication date: September 21, 2023Inventors: Maria Paula CARRANZA SANDMEIER, Rainer FOLLADOR, Veronica Gambillara FONCK, Stefan Jochen KEMMLER, Patricia Martin KILLIAS, Michael Thomas KOWARIK, Gerd Martin LIPOWSKY, Gerald Johann POSCH, Fabio SERVENTI, Dominique Nicolas SIRENA
-
Publication number: 20230226175Abstract: The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising the modified proteins, their manufacture and the use of such compositions in medicine. More particularly, it relates to a modified EPA (Exotoxin A of Pseudomonas aeruginosa) protein. The modified EPA can be used as a carrier protein for other antigens, particularly saccharide antigens or other antigens lacking T cell epitopes.Type: ApplicationFiled: June 17, 2021Publication date: July 20, 2023Inventors: Stefan Jochen KEMMLER, Christian LIZAK, Gerald Johann POSCH, Julien Laurent QUEBATTE
-
Publication number: 20230190926Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).Type: ApplicationFiled: October 6, 2022Publication date: June 22, 2023Inventors: Jeroen GEURTSEN, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Jan Theunis POOLMAN, Kellen Cristhina FAE, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
-
Patent number: 11654190Abstract: The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharide comprising one or more repeat unit(s) ?4)-?-D-Glcp-(1?3)-[[?-L-Rhap-(1?2)]-[Gro-(2?P?3)]-?-D-Galp-(1?4)]-?-L-Rhap-(1?. Also provided are conjugates comprising a ?4)-?-D-Glcp-(1?3)-[[?-L-Rhap-(1?2)]-[Gro-(2?P?3)]-?-D-Galp-(1?4)]-?-L-Rhap-(1?, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.Type: GrantFiled: July 17, 2018Date of Patent: May 23, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Amirreza Faridmoayer, Rainer Follador, Stefan Jochen Kemmler, Michael Thomas Kowarik, Gerd Martin Lipowsky, Gerald Johann Posch, Fabio Serventi
-
Publication number: 20230118878Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: ApplicationFiled: July 28, 2022Publication date: April 20, 2023Inventors: Jeroen GEURTSEN, Jan Theunis POOLMAN, Kellen Cristhina FAE, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
-
Publication number: 20230060184Abstract: The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) ?4)-?-D-Glcp-(1?4)-[Gro-(2?P?3)]-?-D-Galp-(1?4)-?-L-Rhap-(1?. Also provided are conjugates comprising a ?4)-?-D-Glcp-(1?4)-[Gro-(2?P?3)]-?-D-Galp-(1?4)-?-L-Rhap-(1?, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.Type: ApplicationFiled: May 31, 2022Publication date: March 2, 2023Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Amirreza FARIDMOAYER, Rainer FOLLADOR, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Gerald Johann POSCH, Fabio SERVENTI
-
Publication number: 20230062987Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.Type: ApplicationFiled: September 23, 2022Publication date: March 2, 2023Inventors: Jan Theunis POOLMAN, Bert JACQUEMYN, Darren Robert ABBANAT, Patricia Ibarra YON, Peter Wilhelmus Maria HERMANS, Michael Thomas KOWARIK, Michael Lukas WETTER, Stefan Jochen KEMMLER, Micha Andres HÄUPTLE, Veronica Gambillara FONCK, Manuela MALLY
-
Publication number: 20220403347Abstract: The present disclosure provides mutated PglB oligosaccharyltransferase enzymes that have the ability to efficiently catalyze the transfer of a saccharide from a lipid carrier to an asparagine reissue in a glycosylation motif on a protein. Also provided are polynucleotides encoding the mutated PglB oligosaccharyltransferase enzymes, host cells capable of expressing the engineered PglB oligosaccharyltransferase enzymes, and methods of using the engineered PglB oligosaccharyltransferase enzymes to make N-glycosylated proteins. Also provided are N-glycosylated proteins that are made using the engineered PglB oligosaccharyltransferase enzymes.Type: ApplicationFiled: August 6, 2020Publication date: December 22, 2022Inventors: Leigh Anne IHNKEN, Joel KARPIAK, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Joel MELBY, Anne OLLIS, Julien Laurent QUEBATTE
-
Patent number: 11491220Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).Type: GrantFiled: March 18, 2020Date of Patent: November 8, 2022Assignees: Janssen Pharmaceuticals, Inc.Inventors: Jeroen Geurtsen, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Jan Theunis Poolman, Kellen Cristhina Fae, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
-
Patent number: 11484582Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.Type: GrantFiled: February 4, 2020Date of Patent: November 1, 2022Assignees: Janssen Pharmaceuticals, Inc.Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
-
Patent number: 11446370Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: GrantFiled: March 18, 2020Date of Patent: September 20, 2022Assignees: Janssen Pharmaceuticals, Inc., GlaxoSmithKline Biologicals S.A.Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
-
Patent number: 11406696Abstract: The present invention discloses a conjugate comprising an antigen (for example a saccharide antigen) covalently linked to a Pseudomonas aeruginosa PcrV carrier protein comprising an amino acid sequence which is at least 80% identical to the sequence of SEQ ID NO:1-4, wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the P. aeruginosa PcrV carrier protein. The invention also discloses Pseudomonas aeruginosa PcrV proteins that contain glycosylation site consensus sequences.Type: GrantFiled: October 19, 2016Date of Patent: August 9, 2022Inventors: Christiane Marie-Paule Simone Jeanne Feron, Stefan Jochen Kemmler, Michael Thomas Kowarik, Julien Laurent Quebatte
-
Patent number: 11376314Abstract: The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) ?4)-?-D-Glcp-(1?4)-[Gro-(2?P?3)]-?-D-Galp-(1?4)-?-L-Rhap-(1?. Also provided are conjugates comprising a ?4)-?-D-Glcp-(1?4)-[Gro-(2?P?3)]-?-D-Galp-(1?4)-?-L-Rhap-(1?, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.Type: GrantFiled: July 17, 2018Date of Patent: July 5, 2022Inventors: Amirreza Faridmoayer, Rainer Follador, Stefan Jochen Kemmler, Michael Thomas Kowarik, Gerald Johann Posch, Fabio Serventi
-
Publication number: 20220054632Abstract: Carrier proteins modified to incorporate one or more pilin glycotags and applications thereof for O-linked glycosylation are provided. In particular, a modified carrier protein comprising a carrier protein that comprises at least one GlycoTag, wherein the at least one GlycoTag is a Neisseria gonorrhoeae PglL GlycoTag (NgGlycoTag), Neisseria lactamica PglL GlycoTag (NlGlycoTag), or Neisseria shayeganii GlycoTag (NsGlycoTag), or combinations thereof is provided, together with nucleic acids and vectors encoding the modified carrier protein, host cells comprising these modofoed carrier proteins or nucleic acids encoding them, bioconjugates, methods of making bioconjugates and uses of the bioconjugates.Type: ApplicationFiled: December 11, 2019Publication date: February 24, 2022Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Rainer FOLLADOR, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Gerald Johann POSCH
-
Publication number: 20210077607Abstract: The present invention discloses modified Staphylococcus aureus ClfA proteins that contain glycosylation site consensus sequences. The invention also discloses a conjugate comprising a modified ClfA protein and an antigen (for example a Staphylococcus aureus saccharide antigen), wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the modified ClfA protein.Type: ApplicationFiled: December 19, 2018Publication date: March 18, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Amirreza FARIDMOAYER, Sabina Marietta GERBER, Stefan Jochen KEMMLER